Antisense ‘knockdowns’ of M1 receptors induces transient anterograde amnesia in mice
暂无分享,去创建一个
Alessandro Bartolini | Sergio Capaccioli | Alessandro Quattrone | Cristina Bellucci | Fulvio Gualtieri | S. Capaccioli | R. Matucci | A. Quattrone | C. Ghelardini | N. Galeotti | Carla Ghelardini | Nicoletta Galeotti | Rosanna Matucci | F. Gualtieri | A. Bartolini | C. Bellucci
[1] T. Crook,et al. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. , 1991, Nucleic acids research.
[2] S. Capaccioli,et al. Reversion of the invasive phenotype of human fibroblasts by antimessenger oligonucleotide inhibiting the urokinase receptor gene expression , 1994 .
[3] Y. Cheng,et al. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. , 1992, Molecular pharmacology.
[4] M. Giovannini,et al. Stereoselective Increase in Cholinergic Transmission by R-(+)-hyoscyamine , 1997, Neuropharmacology.
[5] S. Capaccioli,et al. Effect of K+ channel modulation on mouse feeding behaviour. , 1997, European journal of pharmacology.
[6] L. Neckers,et al. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Packard,et al. Post-training injection of the acetylcholine M2 receptor antagonist AF-DX 116 improves memory , 1990, Brain Research.
[8] C. F. Bennett,et al. Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.
[9] L. Papucci,et al. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. , 1994, Anti-cancer drug design.
[10] L. Papucci,et al. An antisense oligonucleotide on the mouse Shaker-like potassium channel Kv1.1 gene prevents antinociception induced by morphine and baclofen. , 1997, The Journal of pharmacology and experimental therapeutics.
[11] H. Ladinsky,et al. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine , 1986, British journal of pharmacology.
[12] L. Papucci,et al. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. , 1994, Oncology research.
[13] G. Higgins,et al. Central administration of the muscarinic receptor subtype ‐ selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse , 1983, The Journal of pharmacy and pharmacology.
[14] M. Jarvik,et al. An Improved One-Trial Passive Avoidance Learning Situation , 1967, Psychological reports.
[15] J. Palacios,et al. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies , 1986, Brain Research.
[16] J. Eras,et al. Phosphorothioate oligonucleotides cause degradation of secretory but not intracellular serglycin proteoglycan core protein in a sequence-independent manner in human megakaryocytic tumor cells. , 1995, Antisense research and development.
[17] C. Wahlestedt,et al. Antisense oligonucleotide strategies in neuropharmacology. , 1994, Trends in pharmacological sciences.
[18] J. S. Cohen,et al. Oligodeoxynucleotides as antisense inhibitors of gene expression. , 1992, Progress in nucleic acid research and molecular biology.
[19] T. Haley,et al. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. , 1957, British journal of pharmacology and chemotherapy.
[20] P. Whitehouse. Neuronal Loss and Neurotransmitter Receptor Alterations in Alzheimer’s Disease , 1986 .
[21] C. Ghelardini,et al. S-(-)-ET 126: a potent and selective M1 antagonist in vitro and in vivo. , 1995, Life sciences.
[22] D. Mash,et al. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. , 1985, Science.
[23] J. Goodchild. Inhibition of Gene Expression by Oligonucleotides , 1989 .
[24] R. Bartus,et al. Short-term memory in the rhesus monkey: Disruption from the anti-cholinergic scopolamine , 1976, Pharmacology Biochemistry and Behavior.
[25] L. Squire,et al. Neuroanatomy of memory. , 1993, Annual review of neuroscience.
[26] D Rodbard,et al. Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.
[27] S. Capaccioli,et al. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. , 1993, Biochemical and biophysical research communications.
[28] Y. Cheng,et al. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.
[29] J A Deutsch,et al. The Cholinergic Synapse and the Site of Memory , 1971, Science.
[30] A. Fisher,et al. (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats , 1989, Neuroscience Letters.
[31] D. Braida,et al. Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat. , 1991, European journal of pharmacology.
[32] N. Birdsall,et al. Pirenzepine distinguishes between different subclasses of muscarinic receptors , 1980, Nature.
[33] L. Kedes,et al. Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes , 1985, Molecular and cellular biology.
[34] R. Bartus,et al. The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.
[35] L. Costa,et al. A comparison of the antinociceptive responses to the GABA-receptor agonists THIP and baclofen , 1985, Neuropharmacology.
[36] S. Dei,et al. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. , 1995, Farmaco.
[37] D. Birch,et al. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. , 1992, Nucleic acids research.
[38] F. Roberts,et al. The effect of pirenzepine on spatial learning in the Morris Water Maze , 1988, Pharmacology Biochemistry and Behavior.
[39] L. Nilvebrant,et al. Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites. , 1986, European journal of pharmacology.
[40] L. Papucci,et al. Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method. , 1995, Haematologica.
[41] Alzheimer's and Parkinson's diseases : strategies for research and development , 1986 .
[42] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[43] L. Squire,et al. Structure and function of declarative and nondeclarative memory systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[44] B. Habecker,et al. Isolation, sequence, and functional expression of the mouse M1 muscarinic acetylcholine receptor gene. , 1988, The Journal of biological chemistry.
[45] I. Creese,et al. Reduction in muscarinic receptors by antisense oligodeoxynucleotide. , 1994, Biochemical pharmacology.